By Lawrence HurleyWASHINGTON (Reuters) - The U.S. Supreme Court on Tuesday ruled for Teva Pharmaceutical Industries Ltd in its fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug, by sending the case back to a lower court for further review.On a 7-2 vote, the justices said that the U.S. Court of Appeals for the Federal Circuit had not used the correct approach in analyzing whether the patent in question, due to expire in September 2015, was valid. The appeals court had thrown out the patent, a move that would give generic ...
U.S. Supreme Court rules for Teva over multiple sclerosis drug patent
Reuters |
First Published: Tue, January 20 2015. 21:00 IST
This article is no longer available in our repository.
There could be multiple reasons for this.
You could try searching for this headline on the source website (reuters.com).